search
Back to results

Ultrasound Effects on Glycemic Control in T2DM (U/S_in_T2DM)

Primary Purpose

Type 2 Diabetes

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Ultrasound Delivery
Sponsored by
Yale University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes

Eligibility Criteria

21 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female subjects with a diagnosis of type 2 diabetes ≥ 6 months.
  2. Age ≥ 21 and ≤ 75 years.
  3. Currently on a stable treatment regimen of oral anti-diabetic drugs and not currently prescribed for medication escalation. Oral anti-diabetic drugs are limited to one or more of the following:

    • Metformin
    • Sulfonylureas
    • Meglitinides
    • Thiazolidinediones
  4. HbA1c > 7.0% and < 10% by local laboratory analysis.
  5. Body Mass Index (BMI) ≥ 18 to ≤ 40.0 kg/m2.
  6. Considered generally healthy upon completion of medical history, physical examination and biochemical investigations as judged by the Principal Investigator.
  7. Female subjects must be non-pregnant and non-lactating and have a negative serum pregnancy test at screening and before the ultrasound session.
  8. Ability to provide written informed consent.

Exclusion Criteria:

  1. History or current diagnosis with T1DM or T2DM subjects on insulin, DPP-4 inhibitors, SGLT2 inhibitors, GLP agonists.
  2. A subject who is already indicated for medication escalation of their current diabetic therapy.
  3. A subject who has manifestations of advanced complications from poorly controlled or longstanding diabetes such as diabetic retinopathy, diabetic neuropathy and cardiovascular complications including, but not limited to coronary artery disease, peripheral vascular disease, or cerebrovascular disease such as transient ischemic attack [TIA], cerebral infarct, or cerebral hemorrhage.
  4. History or current diagnosis of cardiac dysrhythmias or heart disease, defined as symptomatic heart failure (New York Heart Association class III or IV), myocardial infarction, unstable angina requiring medication.
  5. Invasive cardiovascular procedure, such as coronary artery bypass graft surgery (CABG), or angioplasty/percutaneous coronary intervention (PCI) within 6 months of screening.
  6. History of recurrent severe hypoglycemia (more than 1 event ≤ 6 month)
  7. Subjects with a history or clinically active malignancy
  8. History of renal disease or abnormal kidney function tests at Screening (glomerular filtration rate [GFR] < 60 mL/min/1.73m2 as estimated using the MDRD equation).
  9. History or active hepatic disease or clinically significant abnormal hepatic function tests at Screening suggestive of hepatic impairment (e.g., ALT and/or AST >2 x ULN, GGT >2 x ULN, total bilirubin > 1 x ULN).
  10. Subjects with a history or presence of any psychiatric disorder that, in the opinion of the Principal Investigator, might confound the results of the trial or pose additional risk in administering the investigational product to the subject.
  11. Personal or family history of hypercoagulability or thromboembolic disease, including deep vein thrombosis and/or pulmonary embolism (PE)
  12. History of surgical treatment for obesity (bariatric surgery, gastric banding, etc.) or any other gastrointestinal surgery (including appendectomy, cholecystectomy), any malabsorption disorder, severe gastroparesis, any GI procedure for weight loss (including LAP-BAND®), as well as clinically significant gastrointestinal disorders (e.g. peptic ulcers, severe GERD) at Screening.
  13. History of any major surgery within 3 months prior to screening.
  14. Any nerve stimulation study or implanted stimulator, including previously or currently implanted vagus nerve stimulator, previously or currently implanted spinal cord stimulator, other implanted electronic medical device, such as implanted pacemaker or cardioverter/ defibrillator (AICD) or history of seizures.
  15. Participation in an investigational study within 30 days prior to dosing or 5 half-lives within the last dose of the investigational product given during the investigational study, whichever is longer.
  16. Current use of any drugs (other than current treatment for diabetes mellitus) that are known to interfere with glucose or insulin metabolism as stated below in table prohibited medication.
  17. Thyroid hormone use is not allowed unless medication is given on a stable dose for at least 3 months prior to screening.
  18. Subject is unable to tolerate adhesive tape or has any unresolved adverse skin reaction in the area of the glucose sensor placement.
  19. Implanted pacemaker or cardioverter/defibrillator (AICD).
  20. History of any active infection, incl. COVID19 (as ruled out by negative PCR test), except mild viral disease, such as common cold, within 30 days prior to screening.
  21. Known history or positive test for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), human immunodeficiency virus type 1 (HIV-1) or type 2 (HIV-2).
  22. History of any recent traumatic injury, including intracerebral hemorrhage and visceral injury.
  23. Donation or loss of > 500 mL of blood or blood product within 2 months prior to screening.
  24. Mental incapacity, unwillingness or language barriers precluding adequate understanding and to follow verbal commands during the ultrasound session or cooperation.
  25. An abdominal ultrasound scan or exam within 1 month prior to screening and/or any pre-planned ultrasound examinations during the study, or the need to participate in any unplanned outside ultrasound procedures during study.
  26. Use of the agents listed in Prohibited Medications Table below (prescription or nonprescription) is prohibited until completion of all study activities.
  27. Identification of risk of hypoglycemia or severely uncontrolled diabetes in screening visit metabolic assessments (CGM, OGTT, and fasting blood draws)

Sites / Locations

  • Yale-New Haven HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

30 minute, dual site stimulation

60 minute, dual site stimulation

Arm Description

Ultrasound Deliveryfor 30 minutes total: 15 minutes on the liver target site and 15 minutes on the intestinal target site.

Ultrasound Delivery for 60 minutes total: 30 minutes on the liver target site and 30 minutes on the intestinal target site.

Outcomes

Primary Outcome Measures

Number of Hepatic Adverse Events - Elevation of liver transaminases AST / ALT.
Number of study participants who develop an elevation of liver transaminases compared to baseline parameters, including AST and ALT. Grade 1 delta ALT and / or AST <3 x ULN; Grade 2 delta ALT and / or AST >3 - 5 x ULN; Grade 3 delta ALT and / or AST >5 - 20 x ULN; Grade 4 delta ALT and / or AST >20 x ULN.

Secondary Outcome Measures

Number of Metabolism and nutrition disorders - Hypoglycemia
Number of study participants who develop Hypoglycemia (- A disorder characterized by laboratory test results that indicate a low concentration of glucose in the blood) after undergoing the study procedure. Grade 1 <LLN - 55 mg/dL; <LLN - 3.0 mmol/L Grade 2 <55 - 40 mg/dL; <3.0 - 2.2 mmol/L Grade 3 <40 - 30 mg/dL; <2.2 - 1.7 mmol/L Grade 4 <30 mg/dL; <1.7 mmol/L; Grade 5 life-threatening consequences; seizures Death

Full Information

First Posted
April 5, 2022
Last Updated
April 24, 2023
Sponsor
Yale University
search

1. Study Identification

Unique Protocol Identification Number
NCT05354947
Brief Title
Ultrasound Effects on Glycemic Control in T2DM
Acronym
U/S_in_T2DM
Official Title
Effects of Multi-Site Abdominal Ultrasound Stimulation on Glycemic Control in T2DM
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 1, 2022 (Actual)
Primary Completion Date
November 2023 (Anticipated)
Study Completion Date
November 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Yale University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is an open label, exploratory pilot study that will assess the effects of dual site focused pulsed ultrasound treatment on glycemic parameters in subjects with T2DM.
Detailed Description
This study will test whether multi-site abdominal ultrasound stimulation can have lasting effects on elevated glucose levels in patients with diabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
30 minute, dual site stimulation
Arm Type
Experimental
Arm Description
Ultrasound Deliveryfor 30 minutes total: 15 minutes on the liver target site and 15 minutes on the intestinal target site.
Arm Title
60 minute, dual site stimulation
Arm Type
Experimental
Arm Description
Ultrasound Delivery for 60 minutes total: 30 minutes on the liver target site and 30 minutes on the intestinal target site.
Intervention Type
Device
Intervention Name(s)
Ultrasound Delivery
Intervention Description
A General Electric LOGIQ E10 ultrasound machine with a C1-6-XD clear probe, will be used to selectively deliver pulsed ultrasound to both, the portal region of the liver and the superior mesenteric plexus.
Primary Outcome Measure Information:
Title
Number of Hepatic Adverse Events - Elevation of liver transaminases AST / ALT.
Description
Number of study participants who develop an elevation of liver transaminases compared to baseline parameters, including AST and ALT. Grade 1 delta ALT and / or AST <3 x ULN; Grade 2 delta ALT and / or AST >3 - 5 x ULN; Grade 3 delta ALT and / or AST >5 - 20 x ULN; Grade 4 delta ALT and / or AST >20 x ULN.
Time Frame
2 weeks
Secondary Outcome Measure Information:
Title
Number of Metabolism and nutrition disorders - Hypoglycemia
Description
Number of study participants who develop Hypoglycemia (- A disorder characterized by laboratory test results that indicate a low concentration of glucose in the blood) after undergoing the study procedure. Grade 1 <LLN - 55 mg/dL; <LLN - 3.0 mmol/L Grade 2 <55 - 40 mg/dL; <3.0 - 2.2 mmol/L Grade 3 <40 - 30 mg/dL; <2.2 - 1.7 mmol/L Grade 4 <30 mg/dL; <1.7 mmol/L; Grade 5 life-threatening consequences; seizures Death
Time Frame
2 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female subjects with a diagnosis of type 2 diabetes ≥ 3 months. Age ≥ 21 and ≤ 75 years. Currently on a stable treatment regimen of oral anti-diabetic drugs and not currently prescribed for medication escalation. Oral anti-diabetic drugs are limited to one or more of the following: Metformin Sulfonylureas Meglitinides Thiazolidinediones HbA1c > 7.0% and < 10% by local laboratory analysis. Body Mass Index (BMI) ≥ 18 to ≤ 40.0 kg/m2. Considered generally healthy upon completion of medical history, physical examination and biochemical investigations as judged by the Principal Investigator. Female subjects must be non-pregnant and non-lactating and have a negative serum pregnancy test at screening and before the ultrasound session. Ability to provide written informed consent. Exclusion Criteria: History or current diagnosis with T1DM or T2DM subjects on insulin, DPP-4 inhibitors, GLP agonists. A subject who is already indicated for medication escalation of their current diabetic therapy. A subject who has manifestations of advanced complications from poorly controlled or longstanding diabetes such as diabetic retinopathy, diabetic neuropathy and cardiovascular complications including, but not limited to coronary artery disease, peripheral vascular disease, or cerebrovascular disease such as transient ischemic attack [TIA], cerebral infarct, or cerebral hemorrhage. History or current diagnosis of cardiac dysrhythmias or heart disease, defined as symptomatic heart failure (New York Heart Association class III or IV), myocardial infarction, unstable angina requiring medication. Invasive cardiovascular procedure, such as coronary artery bypass graft surgery (CABG), or angioplasty/percutaneous coronary intervention (PCI) within 6 months of screening. History of recurrent severe hypoglycemia (more than 1 event ≤ 6 month) Subjects with clinically active malignancy History of renal disease or abnormal kidney function tests at Screening (glomerular filtration rate [GFR] < 60 mL/min/1.73m2 as estimated using the MDRD equation). History or active hepatic disease or clinically significant abnormal hepatic function tests at Screening suggestive of hepatic impairment (e.g., ALT and/or AST >2 x ULN, GGT >2 x ULN, total bilirubin > 1 x ULN). Subjects with a history or presence of any psychiatric disorder that, in the opinion of the Principal Investigator, might confound the results of the trial or pose additional risk in administering the investigational product to the subject. Personal or family history of hypercoagulability or thromboembolic disease, including deep vein thrombosis and/or pulmonary embolism (PE) History of surgical treatment for obesity (bariatric surgery, gastric banding, etc.) or any other gastrointestinal surgery (including appendectomy, cholecystectomy), any malabsorption disorder, severe gastroparesis, any GI procedure for weight loss (including LAP-BAND®), as well as clinically significant gastrointestinal disorders (e.g. peptic ulcers, severe GERD) at Screening. History of any major surgery within 3 months prior to screening. Any nerve stimulation study or implanted stimulator, including previously or currently implanted vagus nerve stimulator, previously or currently implanted spinal cord stimulator, other implanted electronic medical device, such as implanted pacemaker or cardioverter/ defibrillator (AICD) or history of seizures. Participation in an investigational study within 30 days prior to dosing or 5 half-lives within the last dose of the investigational product given during the investigational study, whichever is longer. Current use of any drugs (other than current treatment for diabetes mellitus) that are known to interfere with glucose or insulin metabolism as stated below in table prohibited medication. Thyroid hormone use is not allowed unless medication is given on a stable dose for at least 3 months prior to screening. Subject is unable to tolerate adhesive tape or has any unresolved adverse skin reaction in the area of the glucose sensor placement. Implanted pacemaker or cardioverter/defibrillator (AICD). History of any active infection, incl. COVID19 (as ruled out by negative PCR test), except mild viral disease, such as common cold, within 30 days prior to screening. Known history or positive test for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), human immunodeficiency virus type 1 (HIV-1) or type 2 (HIV-2). History of any recent traumatic injury, including intracerebral hemorrhage and visceral injury. Donation or loss of > 500 mL of blood or blood product within 2 months prior to screening. Mental incapacity, unwillingness or language barriers precluding adequate understanding and to follow verbal commands during the ultrasound session or cooperation. An abdominal ultrasound scan or exam within 1 month prior to screening and/or any pre-planned ultrasound examinations during the study, or the need to participate in any unplanned outside ultrasound procedures during study. Use of the agents listed in Prohibited Medications Table below (prescription or nonprescription) is prohibited until completion of all study activities. Identification of risk of hypoglycemia or severely uncontrolled diabetes in screening visit metabolic assessments (CGM, OGTT, and fasting blood draws)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alice Hahn
Phone
475-321-0504
Email
alice.hahn@yale.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Raimund Herzog, MD
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Yale-New Haven Hospital
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06510
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alice Hahn
Phone
475-321-0504
Email
diabetes.research@yale.edu
First Name & Middle Initial & Last Name & Degree
Raimund Herzog, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Ultrasound Effects on Glycemic Control in T2DM

We'll reach out to this number within 24 hrs